NCT06631326 2026-01-27
HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
First Hospital of China Medical University
Completed
Clinical Trials
9 trialsNCT06435013 2024-05-30
Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC
Sun Yat-sen University
Completed
NCT06253364 2024-03-13
VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy
Tongji Hospital
Completed
NCT04627012 2024-03-06
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Completed
NCT05307926 2022-09-07
Postoperative Adjuvant Therapy of HCC Based on PD-1
Tongji Hospital
Completed
NCT04008082 2022-03-08
A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma
Eisai Inc.
Completed
NCT03663114 2021-01-22
A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma
Eisai Inc.
Completed
NCT04415567 2020-06-04
Adjuvant Lenvatinib Prevents Recurrence of High-risk Patients With HBV-related HCC After Liver Transplantation
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Completed
NCT02430714 2020-01-09
Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
Eisai Inc.
Completed